Pyrazolo[1,5-a]Pyrimidine GABAB Modulators for Brain Penetration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing GABA B receptor ligands, such as baclofen, suffer from poor blood-brain-barrier penetration, narrow therapeutic window, receptor desensitization, and development of tolerance, limiting their therapeutic potential in treating various conditions.
Innovation Solution
Development of pyrazolo[1,5-a]pyrimidine derivatives that act as GABA B receptor positive allosteric modulators, featuring a unique carbon linkage to a six-membered saturated heterocyclic ring, providing high affinity and nanomolar potency, and are brain penetrant.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If orthosteric agonists like baclofen are used to stimulate GABA B receptors, then therapeutic effects are achieved, but blood-brain-barrier penetration is poor and therapeutic window is narrow
Solution Approach 1:
The patent introduces positive allosteric modulators as intermediary substances that bind to a distinct site on the GABA B receptor (not the orthosteric site). These modulators enhance receptor activity indirectly by stabilizing the active conformation of the receptor when GABA is bound, rather than directly activating the orthosteric site. This intermediary mechanism allows for improved blood-brain-barrier penetration and broader therapeutic window while maintaining therapeutic efficacy.
Solution Approach 2:
The patent changes the binding mode parameter from direct orthosteric agonism to allosteric modulation. By modifying how the drug interacts with the receptor (from direct activation to enhancement of endogenous ligand effect), the patent achieves improved pharmacokinetic properties including better blood-brain-barrier penetration and extended therapeutic window, while maintaining the desired therapeutic effect on GABA B receptors.
2Reliability
If orthosteric agonists are used to activate GABA B receptors, then therapeutic benefits are obtained, but receptor desensitization and tolerance develop
Solution Approach 1:
Positive allosteric modulators serve as intermediaries that enhance GABA B receptor activity without directly occupying the orthosteric site. By modulating receptor function allosterically, these compounds prevent the conformational changes and downstream signaling events that lead to receptor desensitization and tolerance, thereby maintaining therapeutic benefits over extended periods without the adverse adaptations seen with orthosteric agonists.
Solution Approach 2:
The patent employs dynamic allosteric modulation rather than static orthosteric activation. Allosteric modulators dynamically enhance receptor response to endogenous GABA, allowing the system to maintain sensitivity and adaptability. This dynamic interaction prevents the fixed conformational locking that occurs with orthosteric agonists, thereby preventing desensitization and tolerance development while sustaining therapeutic effects.
3Reliability
If conventional GABA B receptor ligands are used, then therapeutic effects are achieved, but the therapeutic window is narrow
Solution Approach 1:
The patent changes the fundamental interaction parameter from direct orthosteric agonism to indirect allosteric modulation. This parameter change results in a broader therapeutic window because allosteric modulators can enhance receptor activity in a more graded and controllable manner, allowing for greater flexibility in dosing and response. The modulators can fine-tune receptor activity without the all-or-nothing effect of direct agonists, thereby expanding the range of effective doses and improving adaptability to different therapeutic needs.
Data Source
AI summary
The invention relates to new pyrazolo[1,5-a]pyrimidine derivatives of formula (I) or pharmaceutically acceptable salts, biologically active metabolites, pro-drugs, racemates, enantiomers, diastereomers, solvates and hydrates thereof that serve as GABAB receptor positive allosteric modulators. The invention also relates to the process for producing such compounds and key intermediates used in the process. The invention further relates to pharmaceutical compositions comprising such compounds optionally in combination with two or more different therapeutic agents and the use of such compounds in methods for treating diseases and conditions mediated and modulated by the GABAB receptor positive allosteric mechanism. The invention also provides a method for manufacture of medicaments useful in the treatment of such disorders.